Ampio Reports Successful Type B Pre-IND Meeting With FDA For Zertane To Treat PE

Ampio Says FDA Accepts Modified Questionnaire For Pivotal Trial Of Zertane

Ampio Pharma Initiates Optina Clinical Trial - Quick Facts

Trade AMPE now with

6/21/2012 4:29 AM ET

Ampio Pharmaceuticals, Inc. (AMPE: Quote) announced the outcome of its pre-IND meeting with the CDER Urology and Reproductive group division of the U.S. Food and Drug Administration, or FDA, that took place on June 20, 2012.

FDA gave all the necessary guidance on the design and conduct of two concurrent phase III pivotal clinical trials of around 15 weeks duration. Successful completion of these trials, powered adequately (based on the phase 3 European trials), will allow for FDA clearance to market Zertane as a treatment for life-long premature ejaculation, or PE. These clinical trials would qualify Zertane's registration/clearance under the 505(b) 2 regulatory pathway in the US, the company noted.

Michael Macaluso, Ampio's chief executive officer, said, "We could not be more pleased, as the FDA guidance gave us a clear path to progress our Zertane™ drug through clinical development rapidly, with procedures that permit prompt resolution of the few outstanding issues, so we could commence the trials by the end of this year. This positive guidance will allow us to formalize our negotiations with potential partners. This productive meeting with the FDA was expected by the company because Zertane already successfully completed two phase II and two phase III trials in Europe that met all end points including efficacy and safety."

To receive FREE breaking news email alerts for Ampio Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

81 Articles Next>>

Editors Pick

Stocks Come Under Pressure Amid Worries About The Fed - U.S. Commentary

Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session.

U.S. Durable Goods Orders Rise 3.3% In April, More Than Expected

After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.

Mailbox Now Comes To IPad

The popular e-mail management app Mailbox, developed by Orchestra Inc., has been updated to be compatible with Apple's iPad. Orchestra disclosed the news of the update through its official blog. "You asked, we listened. Mailbox is now available for iPad, so you can swipe your way to inbox zero on all your iOS devices," Orchestra's brief blog read.